Immatics NV and Moderna Forge Billion-Dollar Collaboration to Revolutionize Cancer Therapy

Cambridge, MA, September 11, 2023 (Reuters) -- German drug developer, Immatics NV, is set to receive an impressive initial payment of $120 million. Immatics NV stands to benefit from an array of development, regulatory, and commercial milestone payments that have the potential to exceed a staggering $1.7 billion.

Read full article here.